エンドセリンの産生調節と病態への関与  [in Japanese] Endothelin-1 Production and Its Involvement in Cardiovascular Diseases  [in Japanese]

    • 大喜多 守 OHKITA Mamoru
    • 大阪薬科大学病態分子薬理学研究室 Laboratory of Pathological and Molecular Pharmacology, Osaka University of Pharmaceutical Sciences
    • 高岡 昌徳 TAKAOKA Masanori
    • 大阪薬科大学病態分子薬理学研究室 Laboratory of Pathological and Molecular Pharmacology, Osaka University of Pharmaceutical Sciences
    • 松村 靖夫 MATSUMURA Yasuo
    • 大阪薬科大学病態分子薬理学研究室 Laboratory of Pathological and Molecular Pharmacology, Osaka University of Pharmaceutical Sciences

Abstract

Endothelin (ET) has been implicated in the pathogenesis of several cardiovascular disorders because of its powerful vasoconstrictor and growth-promoting properties. The ET family consists of three isoforms, ET-1, ET-2 and ET-3. ET-1 appears to be the predominant member of the family generated by vascular endothelial cells. In view of the multiple cardiovascular actions of ET-1, there has been much interest in its contribution to the pathophysiology of hypertension and arteriosclerosis. We have been investigating the roles of ET_A and ET_B receptors in ET-1-related cardiovascular diseases using subtype-selective ET receptor antagonists and ET_B receptor-deficient animals. Our studies have demonstrated that ET-1 overproduction and ET_A-mediated ET-1 actions seem to play a crucial role in the development of several types of hypertensive and post-ischemic diseases. On the other hand, ET-1 biosynthesis and release are regulated at the transcriptional level, and various endogenous substances are known to stimulate ET-1 gene expression by DNA binding of transcription factors. We and others have recently demonstrated that nuclear factor-κB (NF-κB), a transcription factor with a pivotal role in inducing genes involved in immune, inflammatory and stress responses, is responsible for endothelial ET-1 production. In in vivo studies, agents that can inhibit the NF-κB activation improved the development of ET-1 related cardiovascular diseases. Thus, NF-κB inhibition may be a pertinent treatment for ET-1 related diseases.

Journal

Journal of the Pharmaceutical Society of Japan   [List of Volumes]

Journal of the Pharmaceutical Society of Japan 127(9), 1319-1329, 2007-09-01  [Table of Contents]

The Pharmaceutical Society of Japan

References:  42

You must have a user ID to see the references.If you already have a user ID, please click "Login" to access the info.New users can click "Sign Up" to register for an user ID.

Preview

Preview

Codes

  • NII Article ID (NAID) :
    110006380717
  • NII NACSIS-CAT ID (NCID) :
    AN00284903
  • Text Lang :
    JPN
  • Article Type :
    REV
  • ISSN :
    00316903
  • NDL Article ID :
    8936826
  • NDL Source Classification :
    ZS51(科学技術--薬学)
  • NDL Call No. :
    Z19-411
  • Databases :
    CJP  NDL  NII-ELS  J-STAGE